2017 American Transplant Congress
A Pretransplant Model Incorporating Serum Biomarkers Is Superior to the Milan Criteria in Stratifying Risk of Hepatocellular Carcinoma Recurrence Following Liver Transplantation: Analysis of 4407 Patients from the US Multicenter HCC Transplant Consortium.
Objective: While adoption of the Milan Criteria (MC) has improved outcomes following liver transplantation (LT) for hepatocellular carcinoma (HCC), recurrence remains a significant challenge. We…2017 American Transplant Congress
Re-Evaluation of Imaging Studies in Patients with Hepatocellular Carcinoma at a Transplant Center Impacts Patient Care.
Organ Transplant, Scripps Clinic, La Jolla, CA
Introduction: The United Network for Organ Sharing (UNOS) requires confirmation of HCC based on imaging to be made at a transplant center. This places a…2017 American Transplant Congress
Sirolimus Prolonged Survival After Living Donor Liver Transplantation for HCC Beynd Milan Criteria; Outcome of a Multicenter Prospective Randomized Phase II Trial (ClinicalTrials.gov Identifier: NCT01374750).
Background:It is unclear whether the reported benefit of mTORi in LT for HCC is from direct effect of mTOR inhibitors. We aimed to compare directly…2017 American Transplant Congress
Predicting Recurrence Prior to Transplant: The Response of HCC to Chemoembolization.
Purpose:This study assesses imaging response characteristics of patients with hepatocellular carcinoma (HCC) to chemoembolization (TACE) as a bridge to transplant and the risk of post-transplant…2017 American Transplant Congress
HCC and Liver Transplantation Following the Recent Allocation Policy Change.
Johns Hopkins University, Baltimore
In October 2015, OPTN implemented a revised liver allocation policy to address the disparity between HCC and non-HCC patients in access to deceased-donor liver transplant…2017 American Transplant Congress
Serum AFP Greater Than 200 ng/ml as a Predictor for Low Survival in Patients with Hepatocelullar Carcinoma Recurrence in a Brazilian Multicentric Study.
Introduction: Liver transplantation (LT) is the only potential curative treatment for hepatocellular carcinoma (HCC) with recurrence (HCC-R) diagnosed in 16%. Aim: The objective of this…2017 American Transplant Congress
ABO-Incompatibility Using Ritiuximab Does Not Increase Hepatocellular Carcinoma Recurrence After Liver Transplantation.
Background and aims: ABO-incompatible (ABO-I) living donor liver transplantation (LDLT) has a high success rate. However, a difference in hepatocellular carcinoma (HCC) recurrence rates has…2017 American Transplant Congress
Comparison of Long-Term Survival Outcome Between Primary Liver Transplantation and Hepatic Resection with Consequent Salvage Transplantation for Hepatocellular Carcinoma within Milan Criteria – A Single-Center Experience.
Background: Whether primary liver transplantation (PLT) is superior to the upfront hepatic resection (HR) and salvage liver transplantation (SLT) for hepatocellular carcinoma (HCC) within Milan…2017 American Transplant Congress
Women in the United States Receive More Resections and Ablations for Hepatocellular Carcinoma Than Men.
1The Ohio State Wexner Medical Center, Columbus; 2The Ohio State University, Columbus
Background: Previous studies have shown conflicting data regarding gender disparities in the treatment of hepatocellular carcinoma. Several studies have suggested that men are more likely…2017 American Transplant Congress
Comparison of Local Recurrence Rates Between Endhole vs Anti-Reflux Catheters in Patients Undergoing DEB-TACE for Solitary LR-5 HCC Tumors.
PurposeTo compare local recurrence rates (LRR), tumor response rates, and dose delivered between standard endhole catheters (EC) versus anti-reflux catheters (AR) in patients who underwent…
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 23
- Next Page »